D. E. Shaw & Co. Inc. Boosts Stock Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)

D. E. Shaw & Co. Inc. increased its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 287.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 222,608 shares of the biopharmaceutical company's stock after purchasing an additional 165,220 shares during the period. D. E. Shaw & Co. Inc. owned 0.45% of Puma Biotechnology worth $679,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in PBYI. Cubist Systematic Strategies LLC purchased a new stake in shares of Puma Biotechnology during the fourth quarter valued at about $99,000. Bank of America Corp DE raised its stake in shares of Puma Biotechnology by 103.1% during the 4th quarter. Bank of America Corp DE now owns 82,339 shares of the biopharmaceutical company's stock worth $251,000 after acquiring an additional 41,790 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in Puma Biotechnology during the fourth quarter valued at approximately $54,000. BNP Paribas Financial Markets boosted its stake in Puma Biotechnology by 9.7% in the fourth quarter. BNP Paribas Financial Markets now owns 74,301 shares of the biopharmaceutical company's stock valued at $227,000 after acquiring an additional 6,599 shares in the last quarter. Finally, Acorn Capital Advisors LLC acquired a new stake in Puma Biotechnology in the fourth quarter valued at approximately $7,475,000. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

Puma Biotechnology Price Performance

Shares of PBYI stock traded up $0.01 during trading hours on Thursday, reaching $3.38. The company had a trading volume of 260,572 shares, compared to its average volume of 436,049. Puma Biotechnology, Inc. has a 12-month low of $2.23 and a 12-month high of $4.13. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The stock has a fifty day moving average of $3.07 and a 200-day moving average of $3.07. The company has a market capitalization of $167.75 million, a price-to-earnings ratio of 7.04 and a beta of 1.29.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The company had revenue of $59.10 million during the quarter, compared to analyst estimates of $52.50 million. On average, equities analysts anticipate that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd. HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Puma Biotechnology in a research report on Friday, February 28th.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.